At the 2021 ASCO Direct virtual conference for Jacksonville, Dr. Ibiayi Dagogo-Jack presented some of the top metastatic lung cancer updates that were shared at the 2021 ASCO Annual Meeting.
First, she will focus on molecular testing/targeting therapy highlighting abstract 9005: Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer and abstract 9006: Amivantamab in combination with Lazertinib for the treatment of Osimertinib-relapsed, chemotherapy-naïve EGFR-mutant NSCLC and potential biomarkers for response.
Then she will move onto immunotherapy studies and share updates from abstract 9000: Nivolumab + ipilimumab + 2 cycles of chemo vs chemo alone in advanced NSCLC: 2-year update from Checkmate9LA and abstract 9002: Pooled analyses of immune-related adverse events and efficacy from the Phase 3 trials IMpower130, IMpower132, and IMpower150.
